What is Biodermis?
Biodermis has established itself as a prominent provider of advanced scar management and post-operative care solutions, leveraging over three decades of industry experience. The company's comprehensive product portfolio features innovative offerings such as Epi-Derm silicone gel sheeting, specialized ointments, and compression foams, all meticulously designed to address a wide spectrum of scar types and surgical recovery needs. Serving a core clientele of medical professionals, including plastic surgeons and dermatologists, as well as individual patients, Biodermis is dedicated to advancing dermatological care through products that optimize the healing process and enhance aesthetic results.
How much funding has Biodermis raised?
Biodermis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Biodermis?
With a substantial history of capital infusion, including its latest strategic investment, Biodermis is well-positioned for continued expansion and innovation in the scar management market. The company's focus on developing advanced skin care solutions suggests a strategic direction aimed at further solidifying its market leadership and potentially exploring new therapeutic areas or product lines. Future growth may involve scaling manufacturing capabilities, expanding market reach through new distribution channels, or investing further in research and development to maintain its competitive edge.
See full Biodermis company page
